Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A comparison of Symbicort® Maintenance and Reliever Therapy (Symbicort Turbuhaler® 160/4.5 μg, one inhalation bid plus as needed) and Symbicort Turbuhaler 160/4.5 μg, one inhalation bid plus terbutaline Turbuhaler 0.4 mg/inhalation as needed, for treatment of asthma – a 12-month, randomized, double-blind, parallel group, active-controlled, multinational phase III study in asthmatic patients aged 16 years and above.

    Summary
    EudraCT number
    		 2008-006869-86
    Trial protocol
    		 HU  
    Global end of trial date
    28 May 2012

    Results information
    Results version number
    		 v1(current)
    This version publication date
    01 Feb 2017
    First version publication date
    02 Aug 2015
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    D589LC00001
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 -
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    AstraZeneca
    Sponsor organisation address
    AstraZeneca R&D, SE-221 87 Lund, Sweden,
    Public contact
    Carin Jorup, AstraZeneca, ClinicalTrialTransparency@astrazeneca.com
    Scientific contact
    Carin Jorup, AstraZeneca, ClinicalTrialTransparency@astrazeneca.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    28 May 2012
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    28 May 2012
    Global end of trial reached?
    Yes
    Global end of trial date
    28 May 2012
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this study is to compare the efficacy of Symbicort® Maintenance and Reliever Therapy (SMART) (Symbicort Turbuhaler® 160/4.5μg, one inhalation bid plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation bid plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy by evaluation of time to first asthma exacerbation.
    Protection of trial subjects
    The final study protocol and amendments (Appendix 12.1.1), including the final version of the Informed Consent Form (Appendix 12.1.3), and the Case Report Form (CRF) (Appendix 12.1.2) were approved or given a favourable opinion in writing by an Institutional Review Board (IRB) as appropriate. The principal investigator at each centre ensured that the patient was given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Patients were also notified that they were free to discontinue from the study at any time. Patients were given the opportunity to ask questions and allowed time to consider the information provided. Parents and the legal representatives (if patient was minor) signed and dated informed consent before conducting any procedure specifically for the study.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    16 Feb 2009
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Argentina: 266
    Country: Number of subjects enrolled
    Brazil: 95
    Country: Number of subjects enrolled
    China: 189
    Country: Number of subjects enrolled
    Costa Rica: 41
    Country: Number of subjects enrolled
    Hungary: 173
    Country: Number of subjects enrolled
    India: 249
    Country: Number of subjects enrolled
    Japan: 400
    Country: Number of subjects enrolled
    Malaysia: 100
    Country: Number of subjects enrolled
    Peru: 70
    Country: Number of subjects enrolled
    Philippines: 198
    Country: Number of subjects enrolled
    Russian Federation: 144
    Country: Number of subjects enrolled
    Korea, Republic of: 105
    Country: Number of subjects enrolled
    Thailand: 61
    Worldwide total number of subjects
    2091
    EEA total number of subjects
    173
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    21
    Adults (18-64 years)
    1865
    From 65 to 84 years
    204
    85 years and over
    1

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 The study was conducted at 148 centres in Japan and in 12 other countries in Asia, America and Europe between 16 February 2009 and 23 February 2011.

    Pre-assignment
    Screening details
    		 The study consisted of an enrolment visit, a 2-week run-in (standardization) period at Visit 2, randomization at Visit 3, and 5 further visits (Visits 4-8) at 4, 12, 24, 36 and 52 weeks. Subjects received 1 of 2 double-blinded treatments allocated in a random order.

    Period 1
    Period 1 title
    Treatment Period (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Monitor, Carer, Data analyst, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Symbicort SMART
    Arm description
    		 Symbicort Turbuhaler® 160/4.5 μg/inhalation
    Arm type
    		 Experimental

    Investigational medicinal product name
    Symbicort® Turbuhaler® 160/4.5 μg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Inhalation powder
    Routes of administration
    Inhalation use
    Dosage and administration details
    160/4.5 μg

    Arm title
    		 Symbicort + Terbutaline
    Arm description
    		 Symbicort Turbuhaler 160/4.5 μg + terbutaline Turbuhaler 0.4 mg/inhalation
    Arm type
    		 Active comparator

    Investigational medicinal product name
    Symbicort® Turbuhaler® 160/4.5 μg + terbutaline Turbuhaler® 0.4 mg/inhalation
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Inhalation powder
    Routes of administration
    Inhalation use
    Dosage and administration details
    160/4.5 μg

    Number of subjects in period 1
    		Symbicort SMART Symbicort + Terbutaline
    Started
    1049
    1042
    Completed
    956
    932
    Not completed
    93
    110
         Consent withdrawn by subject
    28
    34
         Adverse event, non-fatal
    8
    12
         Other reasons
    20
    25
         Lost to follow-up
    31
    26
         Protocol deviation
    6
    13

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Symbicort SMART
    Reporting group description
    		 Symbicort Turbuhaler® 160/4.5 μg/inhalation

    Reporting group title
    Symbicort + Terbutaline
    Reporting group description
    		 Symbicort Turbuhaler 160/4.5 μg + terbutaline Turbuhaler 0.4 mg/inhalation

    Reporting group values
    		 Symbicort SMART Symbicort + Terbutaline Total
    Number of subjects
    		 1049 1042 2091
    Age Categorical
    Units: Subjects
        In utero
    		 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0 0
        Newborns (0-27 days)
    		 0 0 0
        Infants and toddlers (28 days-23 months)
    		 0 0 0
        Children (2-11 years)
    		 0 0 0
        Adolescents (12-17 years)
    		 5 16 21
        Adults (18-64 years)
    		 938 927 1865
        From 65-84 years
    		 106 98 204
        85 years and over
    		 0 1 1
    Age Continuous
    Units: years
        arithmetic mean (full range (min-max))
    		 45.7 (16 to 84) 45.6 (16 to 85) -
    Gender Categorical
    Units: Subjects
        Female
    		 722 692 1414
        Male
    		 327 350 677
    Japanese/Non-Japanese
    Units: Subjects
        Japanese
    		 201 199 400
        Non-Japanese
    		 848 843 1691

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Symbicort SMART
    Reporting group description
    		 Symbicort Turbuhaler® 160/4.5 μg/inhalation

    Reporting group title
    Symbicort + Terbutaline
    Reporting group description
    		 Symbicort Turbuhaler 160/4.5 μg + terbutaline Turbuhaler 0.4 mg/inhalation

    Primary: Total number of asthma exacerbations

    		 Close Top of page
    End point title
    		 Total number of asthma exacerbations
    End point description
    Asthma exacerbations, defined as a deterioration in asthma leading to oral GCS treatment,hospitalization, or ER treatment, were recorded, with the primary outcome variable of time tofirst asthma exacerbation and a secondary outcome variable of the total number of asthmaexacerbations
    End point type
    Primary
    End point timeframe
    52 weeks
    End point values
    		 Symbicort SMART Symbicort + Terbutaline
    Number of subjects analysed
    1049
    1042
    Units: exacerbations
    259
    363
    Statistical analysis title
    		 The time to first asthma exacerbation
    Statistical analysis description
    Cox-proportional hazards model for time to first event
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2091
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.0003
    Method
    		 Regression, Cox
    Parameter type
    		 Hazard ratio (HR)
    Point estimate
    0.695
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.57
         upper limit
    		 0.848
    Statistical analysis title
    		 Total number of asthma exacerbations
    Statistical analysis description
    Analysis of total number of esthma exacerbations reported per subject.
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2091
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Poisson regression
    Parameter type
    		 Risk ratio (RR)
    Point estimate
    0.696
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.592
         upper limit
    		 0.818

    Secondary: Use of as-needed medication

    		 Close Top of page
    End point title
    		 Use of as-needed medication
    End point description
    Total daily no. of inhalations during the treatment period
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    		 Symbicort SMART Symbicort + Terbutaline
    Number of subjects analysed
    1032
    1026
    Units: days
        arithmetic mean (full range (min-max))
    1.21 (0 to 9.3)
    1.46 (0 to 15)
    Statistical analysis title
    		 Change from baseline in use of as-needed med.
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2058
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.001
    Method
    		 ANOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    -0.25
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -0.36
         upper limit
    		 -0.15

    Secondary: Morning PEF (L/min)

    		 Close Top of page
    End point title
    		 Morning PEF (L/min)
    End point description
    Mean value during the treatment period
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    		 Symbicort SMART Symbicort + Terbutaline
    Number of subjects analysed
    1034
    1026
    Units: (L/min)
        arithmetic mean (full range (min-max))
    331.8 (98 to 752)
    324.7 (87 to 725)
    Statistical analysis title
    		 Change from baseline in mean morning PEF (L/min)
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2060
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.002
    Method
    		 ANOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    5.8
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 2.1
         upper limit
    		 9.5

    Secondary: Evening PEF (L/min)

    		 Close Top of page
    End point title
    		 Evening PEF (L/min)
    End point description
    Mean evening PEF during the treatment period
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    		 Symbicort SMART Symbicort + Terbutaline
    Number of subjects analysed
    1034
    1026
    Units: (L/min)
        arithmetic mean (full range (min-max))
    334.2 (96 to 725)
    327.8 (85 to 723)
    Statistical analysis title
    		 Change from baseline in mean evening PEF(L/min)
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2060
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.002
    Method
    		 ANOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    5.7
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 2.1
         upper limit
    		 9.3

    Secondary: Asthma symptom score

    		 Close Top of page
    End point title
    		 Asthma symptom score
    End point description
    Mean Total score(0-6) during the treatment period
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    		 Symbicort SMART Symbicort + Terbutaline
    Number of subjects analysed
    1034
    1025
    Units: average score
        arithmetic mean (full range (min-max))
    1.12 (0 to 5.9)
    1.22 (0 to 5.5)
    Statistical analysis title
    		 Mean asthma symptoms (total score)
    Statistical analysis description
    Change from baseline in mean asthma symptoms (total)
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2059
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.025
    Method
    		 ANOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    -0.08
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -0.16
         upper limit
    		 -0.01

    Secondary: Nights with awakenings due to asthma symptoms(%)

    		 Close Top of page
    End point title
    		 Nights with awakenings due to asthma symptoms(%)
    End point description
    % nights with awakenings during the treatment period
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    		 Symbicort SMART Symbicort + Terbutaline
    Number of subjects analysed
    1024
    1025
    Units: Proportion of nights
        arithmetic mean (full range (min-max))
    15.7 (0 to 100)
    15.5 (0 to 100)
    Statistical analysis title
    		 % of nights with awakenings due to asthma
    Statistical analysis description
    Change from baseline in % of nights with awakenings due to asthma
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2049
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.06
    Method
    		 ANOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    -1.8
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -3.68
         upper limit
    		 0.07

    Secondary: Symptom free days (%)

    		 Close Top of page
    End point title
    		 Symptom free days (%)
    End point description
    % of symptom free days during the treatment period
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    		 Symbicort SMART Symbicort + Terbutaline
    Number of subjects analysed
    1034
    1026
    Units: days
        arithmetic mean (full range (min-max))
    45.5 (0 to 100)
    41.6 (0 to 100)
    Statistical analysis title
    		 Change from baseline in % Symptom free days
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2060
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.016
    Method
    		 ANOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    3.6
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.69
         upper limit
    		 6.5

    Secondary: Percentage of asthma-control days

    		 Close Top of page
    End point title
    		 Percentage of asthma-control days
    End point description
    % of asthma control days during the treatment period
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    		 Symbicort SMART Symbicort + Terbutaline
    Number of subjects analysed
    1033
    1026
    Units: percentage
        arithmetic mean (full range (min-max))
    41.7 (0 to 100)
    37.9 (0 to 100)
    Statistical analysis title
    		 Change from baseline in % of asthma-control days
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2059
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.005
    Method
    		 ANOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    4.2
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 1.3
         upper limit
    		 7.1

    Secondary: Mean FEV1 (L)

    		 Close Top of page
    End point title
    		 Mean FEV1 (L)
    End point description
    Mean FEV1 during the treatment period
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    		 Symbicort SMART Symbicort + Terbutaline
    Number of subjects analysed
    1049
    1042
    Units: Liters
        arithmetic mean (full range (min-max))
    2.258 (0.64 to 5.05)
    2.222 (0.68 to 5.77)
    Statistical analysis title
    		 change from baseline in mean FEV1 (L)
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2091
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.001
    Method
    		 ANCOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    0.04
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.015
         upper limit
    		 0.064

    Secondary: Mild asthma exacerbations

    		 Close Top of page
    End point title
    		 Mild asthma exacerbations
    End point description
    Patients with at least one mild exacerbation
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    		 Symbicort SMART Symbicort + Terbutaline
    Number of subjects analysed
    1049
    1042
    Units: number of exacerbations
    739
    825
    Statistical analysis title
    		 Time to first mild exacerbation
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2091
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Regression, Cox
    Parameter type
    		 Hazard ratio (HR)
    Point estimate
    0.811
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.734
         upper limit
    		 0.896
    Statistical analysis title
    		 Number of mild asthma excerbations (days)
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2091
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.0276
    Method
    		 Poisson regression
    Parameter type
    		 Risk ratio (RR)
    Point estimate
    0.889
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 0.8
         upper limit
    		 0.987

    Secondary: ACQ score

    		 Close Top of page
    End point title
    		 ACQ score
    End point description
    Mean overall ACQ score during the treatment period
    End point type
    Secondary
    End point timeframe
    52 weeks
    End point values
    		 Symbicort SMART Symbicort + Terbutaline
    Number of subjects analysed
    1040
    1038
    Units: average score
        arithmetic mean (full range (min-max))
    1.162 (0 to 5.88)
    1.289 (0 to 4.68)
    Statistical analysis title
    		 Change from baseline in mean ACQ score
    Comparison groups
    Symbicort SMART v Symbicort + Terbutaline
    Number of subjects included in analysis
    2078
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.001
    Method
    		 ANOVA
    Parameter type
    		 Mean difference (final values)
    Point estimate
    -0.124
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -0.179
         upper limit
    		 -0.069

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse events were collected from the run-in visit (visit 2) until visit 8 (52 weeks after randomisation). AEs observed after intake of the investigational product are presented in the summaries below.
    Adverse event reporting additional description
    A total of 1201 patients reported non-serious adverse events; 602 on Symbicort SMART, 599 on Symbicort + Terbutaline. Numbers for non-serious AEs in the reporting group table are based on the 5% threshold frequency.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    13.1
    Reporting groups
    Reporting group title
    Symbicort + Terbutaline
    Reporting group description
    		 Symbicort Turbuhaler 160/4.5 μg + terbutaline Turbuhaler 0.4 mg/inhalation

    Reporting group title
    Symbicort SMART
    Reporting group description
    		 Symbicort Turbuhaler® 160/4.5 μg/inhalation

    Serious adverse events
    		 Symbicort + Terbutaline Symbicort SMART
    Total subjects affected by serious adverse events
         subjects affected / exposed
    75 / 1042 (7.20%)
    43 / 1049 (4.10%)
         number of deaths (all causes)
    1
    1
         number of deaths resulting from adverse events
    1
    1
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Breast cancer in situ
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    intestinal adenocarcinoma
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    metastatic neoplasm
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rectal cancer
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Uterine leiomyoma
         subjects affected / exposed
    0 / 1042 (0.00%)
    2 / 1049 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vascular disorders
    hypertension
         subjects affected / exposed
    1 / 1042 (0.10%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pregnancy, puerperium and perinatal conditions
    abortion spontaneous
         subjects affected / exposed
    1 / 1042 (0.10%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    abortion threatened
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    premature baby
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    hernia obstructive
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    malaise
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    pyrexia
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Immune system disorders
    drug hypersensitivity
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    breast calcifications
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    dysfunctional uterine bleeding
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    endometriosis
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    infertility male
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    31 / 1042 (2.98%)
    5 / 1049 (0.48%)
         occurrences causally related to treatment / all
    0 / 38
    2 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dyspnoea
         subjects affected / exposed
    2 / 1042 (0.19%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nasal septum deviation
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    major depression
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    foot fracture
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    joint injury
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    lower limb fracture
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    muscle strain
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    patella fracture
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    sternal fracture
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    traumatic brain injury
         subjects affected / exposed
    2 / 1042 (0.19%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Congenital, familial and genetic disorders
    cleft lip
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    acute myocardial infarction
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    angina pectoris
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    angina unstable
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    coronary artery disease
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    convulsion
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    dizziness
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    headache
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    syncope
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    menieres disease
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    cataract
         subjects affected / exposed
    1 / 1042 (0.10%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    retinal detachment
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 1042 (0.00%)
    3 / 1049 (0.29%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal hernia
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Acute abdomen
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Anal fissure
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    colonic polyp
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    diarrhoea
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    gastric polyps
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    cholelithiasis
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    hepatotoxicity
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    rash
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    haematuria
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endocrine disorders
    basedows disease
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Musculoskeletal and connective tissue disorders
    back pain
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    intervertebral disc protrusion
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    rheumatoid arthritis
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Gastroenteritis
         subjects affected / exposed
    3 / 1042 (0.29%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    2 / 1042 (0.19%)
    4 / 1049 (0.38%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Acute sinusitis
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Breast abscess
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchitis
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Bronchopneumonia
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    h1n1 influenza
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lower respiratory tract infection bacterial
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Osteomyelitis
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Otitis media chronic
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia bacterial
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Sinusitis
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tooth abscess
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tracheobronchitis
         subjects affected / exposed
    0 / 1042 (0.00%)
    2 / 1049 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Upper respiratory tract infection bacterial
         subjects affected / exposed
    0 / 1042 (0.00%)
    2 / 1049 (0.19%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Varicella
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Viral infection
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Viral upper respiratory tract infection
         subjects affected / exposed
    0 / 1042 (0.00%)
    1 / 1049 (0.10%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    diabetes mellitus
         subjects affected / exposed
    1 / 1042 (0.10%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    type 2 diabetes mellitus
         subjects affected / exposed
    2 / 1042 (0.19%)
    0 / 1049 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Symbicort + Terbutaline Symbicort SMART
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    350 / 1042 (33.59%)
    314 / 1049 (29.93%)
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    75 / 1042 (7.20%)
    49 / 1049 (4.67%)
         occurrences all number
    102
    60
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    78 / 1042 (7.49%)
    69 / 1049 (6.58%)
         occurrences all number
    96
    87
    Nasopharyngitis
         subjects affected / exposed
    133 / 1042 (12.76%)
    137 / 1049 (13.06%)
         occurrences all number
    2116
    230
    Viral upper respiratory tract infection
         subjects affected / exposed
    72 / 1042 (6.91%)
    60 / 1049 (5.72%)
         occurrences all number
    87
    71
    Pharyngitis
         subjects affected / exposed
    58 / 1042 (5.57%)
    49 / 1049 (4.67%)
         occurrences all number
    69
    65

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    29 Jan 2009
    Add the explanation that FEV1 predicted normal values for adolescents (age 16 and 17 years) was calculated according to Polgar and reference.
    14 Jul 2009
    Add humanised monoclonal antibody to IgE. Change the post- bronchodilatory FEV1 to the pre-bronchodilatory FEV1

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 10:59:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA